Request Demo

Last update 02 Oct 2025

Cabergoline

Last update 02 Oct 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide, 1-((6-allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea

+ [15]

Target

D2 receptor

Action

agonists

Mechanism

D2 receptor agonists(Dopamine D2 receptor agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [1]

Active Indication

Lactation DisordersParkinson DiseaseHyperprolactinemia

Inactive Indication

Restless Legs Syndrome

Originator Organization

Pfizer Inc.

Active Organization

Strides Pharma Global Pte Ltd.

Pfizer Japan, Inc.

Pfizer Inc.

+ [1]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Australia (21 Apr 1995),

Hyperprolactinemia

Regulation-

Structure/Sequence

Molecular FormulaC26H37N5O2

InChIKeyKORNTPPJEAJQIU-KJXAQDMKSA-N

CAS Registry81409-90-7

107

Clinical Trials associated with Cabergoline

NCT07045935

/ RecruitingPhase 4IIT

Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment - A Randomized, Single-Blind Active- Controlled Trial

This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral glucose tolerance test.

Start Date16 Sep 2025

Sponsor / Collaborator-

NCT07072910

/ Not yet recruitingPhase 2IIT

Prevention and Treatment of Episodic Migraine by Cabergoline Therapy (PROTECT). A Randomized, Placebo-controlled, Double-blind, Investigator-initiated Trial

The goal of this randomized, placebo-controlled, double-blind clinical trial is to evaluate the efficacy, safety, and tolerability of cabergoline for the prevention of episodic migraine in adults with 4-14 monthly migraine days (MMD). The main questions it aims to answer are:
1. Does once-weekly cabergoline (0.5 mg or 1.0 mg) reduce MMD compared to placebo?
2. What are the effects of cabergoline on headache severity, acute medication use, and patient-reported outcomes?
3. Is cabergoline safe to use in individuals with migraine?
Participants will:
Complete a 4-week baseline period to document migraine frequency and classify headache days.
Be randomly assigned to one of three treatment arms:
1. Cabergoline 0.5 mg/week
2. Cabergoline 1.0 mg/week
3. Placebo
Participate in a 12-week double-blind treatment phase, followed by a 12-week open-label treatment phase where all participants receive cabergoline (0.5 mg or 1.0 mg once weekly).
Record daily headache activity, acute medication use, and severity using an electronic diary.
Complete validated headache questionnaires and provide blood samples for biomarker analysis at baseline, week 12, and week 24.
The study also includes exploratory analyses of genetic predictors of treatment response and metabolic markers to assess the broader effects of cabergoline.

Start Date01 Sep 2025

Sponsor / Collaborator

University of Aarhus

NCT07124221

/ RecruitingPhase 3

A Randomized, Double-blind, Double-dummy, Positive Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets in Female Patients With Hyperprolactinemia

A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia

Start Date12 Sep 2025

Sponsor / Collaborator

Changchun Genescience Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Cabergoline

100 Translational Medicine associated with Cabergoline

100 Patents (Medical) associated with Cabergoline

2,206

Literatures (Medical) associated with Cabergoline

01 Jan 2026·THERIOGENOLOGY

Effect of kisspeptin with or without cabergoline on the estrus cycle and reproductive hormones in female dogs

Article

Author: Cortu, Atakan ; Schäfer-Somi, Sabine ; Agaoglu, Ali Reha ; Aslan, Selim ; Bozkurt, Gökhan ; Wehrend, Axel ; Tepik, Feride Zabitler

This study aimed to evaluate the effects of Kisspeptin (KP-10) and Cabergoline (CB) on hormonal regulation in anestrus female dogs. Twenty-three clinically healthy anestrus female dogs were randomly allocated into five treatment groups. Group 1 (G1, n = 4) received CB with saline; Group 2 (G2, n = 4) received 0.5 μg/kg KP-10 + CB; Group 3 (G3, n = 5) received 1 μg/kg KP-10 + CB; Group 4 (G4, n = 5) received 0.5 μg/kg KP-10 alone; and Group 5 (G5, n = 5) received 1 μg/kg KP-10 alone. KP-10 was administered intravenously as a single dose, while CB was given orally for 15 consecutive days. Blood samples were collected at multiple time points to measure serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), and progesterone (P4). Results showed that LH and FSH concentrations increased significantly in a dose-dependent manner in groups receiving KP-10 alone (G4, G5), with G2 showing the lowest increase. Only G3 exhibited a P4 increase above 2 ng/mL on day 15, suggesting possible luteinization. CB alone (G1) had minimal effects on hormone levels. E2 levels increased in all groups, although not reaching proestrus levels. KP-10, particularly at 1 μg/kg (G3, G5), effectively stimulated LH and FSH release but did not induce clinical estrus. The short-term CB regimen was insufficient, emphasizing the need for an extended duration of administration. KP-10 alone appears promising for inducing gonadotropin release; however, in the absence of proestrus bleeding or behavioral signs of estrus, its efficacy in triggering a complete estrous response remains uncertain. Further research is needed to clarify whether the observed hormonal changes can induce clinical estrus.

01 Oct 2025·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Harnessing integrated bioinformatics to identify new diagnostic and therapeutic strategies for heart failure

Article

Author: Wang, Ruilin ; Shang, Min ; Fu, Guosheng ; Sun, Shuo ; Huang, Chengchen ; Lai, Chaojie

Heart failure (HF) is a life-threatening condition that poses a significant challenge on public health, particularly among the elder populations. To develop new diagnostic and therapeutic strategies for HF, we analyzed large-scale transcriptome sequencing data from HF patients as an exploratory approach. We identified 18 HF-related genes and developed a robust scoring model for HF diagnosis, by applying two machine learning algorithms for data analysis. Meanwhile, we evaluated and compared the predictive abilities of three bioinformatics methods in identifying potential HF treatment drugs. Significantly, an unconventional network-based proximity analysis, integrating multidimensional drug target information, outperformed other methods in the assessment of predictive ability. To validate these findings, we tested several candidate drugs in a mouse model transitioning from acute myocardial infarction (MI) to chronic HF. Among the candidates, mirtazapine exhibited cardioprotective effects in both early (1-week) post-MI and chronic HF (4-week post-MI) settings, while cabergoline showed potential efficacy primarily in the early post-MI phase. Additionally, the screened triamterene, used as a positive control, exhibited protective effects in both early post-MI and chronic HF stages. Mechanistic studies revealed that growth factor receptor-bound protein 14 and Ras-related protein Rab-3A were critical to the observed cardioprotection. These findings provide valuable evidence and insights for exploring potential therapeutic agents for HF treatment.

01 Oct 2025·SLEEP MEDICINE

Partial endorsement of “Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline” by the World Sleep Society

Article

Author: Ferri, Raffaele ; Manconi, Mauro ; Silber, Michael H ; Trenkwalder, Claudia ; Kushida, Clete A ; Inoue, Yuichi

BACKGROUND:

The 2025 American Academy of Sleep Medicine (AASM) clinical practice guideline for the treatment of Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD) provides updated, evidence-based recommendations. The World Sleep Society (WSS) conducted an international review to assess the guideline's global applicability and implementation feasibility.

METHODS:

A structured questionnaire was distributed to representatives of 53 national sleep societies affiliated with the WSS. The survey addressed guideline familiarity, perceived applicability, agreement with 20 treatment recommendations, and availability of key therapies. Responses were analyzed using descriptive statistics and the within-group interrater agreement coefficient (rWG) to assess consensus levels.

RESULTS:

Twenty-three national societies (43.9 %) from all inhabited continents responded. The AASM guideline was perceived as fully or partially applicable in most countries. Twelve recommendations were fully supported by the WSS, five partially supported, two (regarding dopamine agonists) endorsed with caveats, and one (dipyridamole) not supported. Key barriers included limited access to certain medications (e.g., IV iron, gabapentin enacarbil), regulatory restrictions, and divergent treatment traditions. There was strong global consensus on discouraging ineffective or harmful treatments (e.g., cabergoline, valproic acid), while the avoidance of dopaminergic agents generated regional disagreement.

CONCLUSIONS:

The AASM guidelines received broad international support but require region-specific adaptation for optimal implementation. The WSS endorses the guideline's structure and scientific foundation while recommending flexible dissemination strategies and greater clarity in therapeutic algorithms. These findings support the development of globally relevant, context-sensitive guidance in sleep medicine.

News (Medical) associated with Cabergoline

15 May 2025

·www.prnewswire.com

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight

The Cushing's disease pipeline possesses some drugs in mid and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including relacorilant, clofutriben, atumelnant, and others. The expected launch of these therapies shall further create a positive impact on the Cushing's disease market. LAS VEGAS, May 15, 2025 /PRNewswire/ -- DelveInsight's Cushing's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Cushing's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Cushing's Disease Market Report According to DelveInsight's analysis, the market size for Cushing's disease was found to be USD 1 billion in the 7MM in 2024. In 2024, among all the current therapies for Cushing's disease, the highest revenue was generated by Mifepristone (KORLYM and generics) in the US. Based on DelveInsight's assessment in 2024, the 7MM had approximately 37K diagnosed prevalent cases of Cushing's disease. These cases are expected to rise due to advancements in diagnostic capabilities and increased awareness about the disease during the forecast period (2025–2034). Leading Cushing's disease companies developing emerging therapies, such as Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others, are developing novel Cushing's disease drugs that can be available in the Cushing's disease market in the coming years. The promising Cushing's disease therapies in the pipeline include DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), Volixibat, and others. In March 2025, Corcept Therapeutics announced that the FDA had assigned a PDUFA target action date of December 30, 2025, for relacorilant to treat patients with endogenous hypercortisolism. In February 2025, Crinetics Pharmaceuticals mentioned that the company anticipates beginning enrollment for Atumelnant (CRN04894) in Phase Ib/IIa trials for Cushing's disease in late 2025 or early 2026. In October 2024, Sparrow Pharmaceuticals announced that clofutriben had been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of endogenous Cushing's syndrome. Discover which therapies are expected to grab the major Cushing's disease market share @ Cushing's Disease Market Report Cushing's Disease Overview Cushing's disease is a rare but serious endocrine disorder caused by a pituitary tumor that triggers excessive cortisol production. It presents with a variety of symptoms such as weight gain, fatigue, mood disturbances, high blood pressure, and impaired glucose tolerance. Cushing's syndrome is responsible for 80–85% of hypercortisolism cases, with 75–80% of those linked to ACTH-producing pituitary adenomas. Without treatment, the 5-year survival rate is only about 50%, emphasizing the urgent need for effective therapies. Diagnosing Cushing's disease is especially difficult because it is rare, shares symptoms with other disorders, and presents in various ways. Only 40–60% of patients have a detectable tumor on standard Magnetic Resonance Imaging (MRI), and the diagnosis is often delayed by an average of 7 years. Cushing's Disease Epidemiology Segmentation The Cushing's disease epidemiology section provides insights into the historical and current Cushing's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The Cushing's disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Cushing's Disease Total Diagnosed Prevalent Cases of Cushing's Disease Gender-Specific Diagnosed Prevalent Cases of Cushing's Disease Age-Specific Diagnosed Prevalent Cases of Cushing's Disease Cushing's Disease Treatment Market The primary treatment for Cushing's disease is usually transsphenoidal surgery to remove the pituitary tumor, which often leads to remission. However, some patients may experience a recurrence. When surgery is unsuccessful or not an option, medical therapies are used to control cortisol levels. Various medications are available for managing Cushing's disease, especially in cases where surgery is ineffective or not feasible. One such drug is KORLYM, developed by Corcept Therapeutics, approved for treating hyperglycemia in patients with Cushing's syndrome who also have Type 2 diabetes or glucose intolerance. In 2024, a generic version by Teva Pharmaceuticals entered the market, adding competition, and Corcept itself has released a generic version as well. Other approved options include S IGNIFOR and SIGNIFOR LAR, ISTURISA, and RECORLEV. In addition, off-label drugs like ketoconazole, metyrapone, cabergoline, mitotane, and etomidate are also used in the U.S., with some marketed in Europe by HRA Pharma. SIGNIFOR (pasireotide), developed by Recordati, was the first drug specifically approved for Cushing's disease by the FDA in 2012, and also gained EU approval. Recordati also markets SIGNIFOR LAR, a long-acting injectable version approved by the FDA and Japan's PMDA in 2018. This formulation, administered intramuscularly once every four weeks, shares the same mechanism as SIGNIFOR but offers a different delivery route. Recordati is recognized as a leading player in this therapeutic area. Another key product from the company is ISTURISA (osilodrostat), the first FDA-approved oral drug that inhibits cortisol production by targeting the enzyme 11β-hydroxylase (CYP11B1), which is involved in the final step of cortisol synthesis. Its oral administration makes it more convenient for patients compared to injectable therapies. ISTURISA is also being studied for pediatric use in an ongoing Phase II trial (NCT03708900). RECORLEV, originally developed by Strongbridge Biopharma and later acquired by Xeris Pharmaceuticals, was approved by the FDA in 2021. It is indicated for adults with endogenous Cushing's syndrome who are not surgical candidates or did not achieve a cure through surgery. Unlike ISTURISA, RECORLEV works by inhibiting cortisol production at multiple points in the steroidogenesis pathway, offering a distinct mechanism of action. To know more about Cushing's disease treatment guidelines, visit @ Cushing's Disease Management Cushing's Disease Pipeline Therapies and Key Companies Relacorilant (CORT125134): Corcept Therapeutics Clofutriben (SPI-62): Sparrow Pharmaceuticals Atumelnant (CRN04894): Crinetics Pharmaceuticals Lu AG13909: H. Lundbeck ST-002: Stero Therapeutics Discover more about Cushing's disease drugs in development @ Cushing's Disease Clinical Trials Cushing's Disease Market Dynamics The Cushing's disease market dynamics are expected to change in the coming years. Although Cushing's disease is generally considered a rare condition, growing awareness and recent advances in research suggest that diagnoses may rise in the future; despite a seemingly crowded market, many current hypercortisolism treatments fail to normalize cortisol levels effectively and pose significant side effects highlighting a substantial opportunity for innovation, especially given the limited therapies specifically targeting Cushing's disease and the potential of newer oral alternatives like ISTURISA and RECORLEV to offer greater flexibility compared to SC and intramuscular options such as SIGNIFOR and SIGNIFOR LAR. Furthermore, potential therapies are being investigated for the treatment of Cushing's disease, and it is safe to predict that the treatment space will significantly impact the Cushing's disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Cushing's disease market in the 7MM. However, several factors may impede the growth of the Cushing's disease market. Due to non-specific guidelines and recommendations, patients with Cushing's disease often face suboptimal care, delayed diagnosis, and inconsistent treatment approaches, further compounded by the diagnostic complexity, frequent misdiagnosis, and symptom overlap with more common conditions, which leave many undiagnosed or untreated; while existing therapies such as ketoconazole and metyrapone approved in Europe based on limited retrospective data and used off-label in the US despite high costs are widely trusted and entrenched in clinical practice, posing a significant barrier to the adoption of emerging therapies. Moreover, Cushing's disease treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Cushing's disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Cushing's disease market growth. Scope of the Cushing's Disease Market Report Therapeutic Assessment: Cushing's Disease current marketed and emerging therapies Cushing's Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Cushing's Disease Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cushing's Disease Market Access and Reimbursement Download the report to understand which factors are driving Cushing's disease market trends @ Cushing's Disease Market Trends Table of Contents Related Reports Cushing's Syndrome Market Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Cushing's Syndrome Pipeline Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Endogenous Cushing's Syndrome Market Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endogenous Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. Endogenous Cushing's Syndrome Pipeline Endogenous Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endogenous Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalOrphan DrugPhase 2

02 Dec 2024

·www.drugs.com

Guidelines Developed for Treatment of Restless Legs Syndrome

MONDAY, Dec. 2, 2024 -- In a clinical practice guideline issued by the American Academy of Sleep Medicine and published online Sept. 26 in the Journal of Clinical Sleep Medicine , recommendations are presented for the treatment of restless legs syndrome (RLS). John W. Winkelman, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues developed recommendations for treatment of RLS and periodic limb movement disorder in adults and pediatric patients. The researchers developed three good practice statements that were based on expert consensus. They recommend all clinicians should regularly test serum iron studies, including ferritin and transferrin saturation, in all patients with clinically significant RLS, ideally in the morning; analysis of these studies influences the decision to use oral or intravenous (IV) iron treatment. The authors also state that addressing exacerbating factors, including alcohol, caffeine, antihistaminergic, serotonergic, and anti-dopaminergic medications, should be the first step in RLS management. They note RLS is common in pregnancy and the pregnancy-specific safety profile of each treatment should be considered. Recommendations for adults with RLS include use of gabapentin enacarbil over no gabapentin enacarbil; use of gabapentin over no gabapentin; use of pregabalin over no pregabalin; and use of IV ferric carboxymaltose over no IV ferric carboxymaltose for those with appropriate iron status (strong recommendations; moderate certainty of evidence). In addition, there is a strong recommendation against use of cabergoline. "Guided by the best evidence in the scientific literature, we've provided recommendations that will improve the ability of clinicians to provide patient-centered care for people who have RLS," Winkelman said in a statement. One author disclosed ties to the pharmaceutical and medical device industries. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

06 Dec 2021

·www.pharmaindustrial-india.com

IPC adds 9 new IP impurities standards

The Indian Pharmacopoeia Commission (IPC) has added 9 new IP impurities standards which includes Bromhexine Hydrochloride Impurity C, Cabergoline Impurity A, Cilostazol Impurity B, Citalopram Impurity B, Fosinopril Impurity A, o-toluene sulfonamide, p-toluene sulfonamide, Tributyl o-acetyl citrate/Acetyl Tributyl citrate, Vildagliptin Impurity D. Impurity standards are used to perform the system suitability, qualitative and quantitative parameters for compliance to Indian Pharmacopoeia monograph. The commission stated that certain monographs require the use of a chemical reference substance or a biological reference preparation or a reference spectrum. IPC in collaboration with USP also conducted a webinar on “Fundamentals of Dissolution” as a part of Capability Building initiative. The webinar was conducted “exclusively” for MSME (Micro, small and medium enterprises). The session conducted by Dr. Rajeev Singh Raghuvanshi - Secretary-cum-Scientific Director, IPC and Josan Thomas, Scientific Liaison, USP India, covered the science behind dissolution, fundamentals of dissolution testing, and specifics related to the qualification of USP apparatus 1 and apparatus 2. The session saw great response with 339 participants from 149 unique companies. The panelists for webinar includes Dr. Rajeev Singh Raghuvanshi - Secretary-cum-Scientific Director, IPC, Dr. Robin Kumar - Principal Scientific Officer, Dr. Gaurav Pratap Singh Jadaun - Senior Scientific Officer, IPC, Josan Thomas, Scientific Liaison, USP India, Mr. Girish Kapur- Vice President, USP India, Joseph Eaton - Senior Manager, USP Rockville. The vision of IPC is to promote the highest standards of drugs for use in human and animals within practical limits of the technologies available for manufacture and analysis. IPC is an autonomous institution of the ministry of health and family welfare, Government of India. IPC is created to set standards of drugs in the country. Its basic function is to update regularly the standards of drugs commonly required for treatment of diseases prevailing in this region. The mandate of the commission is to perform, inter-alia, functions such as revision and publication of the Indian Pharmacopoeia and National Formulary of India on a regular basis besides providing IP reference substances and training to the stakeholders on pharmacopoeial issues

100 Deals associated with Cabergoline

External Link

KEGG	Wiki	ATC	Drug Bank
D00987	Cabergoline	N04BC06 G02CB03	DB00248

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lactation Disorders	Japan	Pfizer Japan, Inc.	16 Apr 2003
Parkinson Disease	Japan	Pfizer Japan, Inc.	16 Jun 1999
Hyperprolactinemia	Australia	Pfizer Inc.	21 Apr 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Restless Legs Syndrome	Phase 3	-	Pfizer Inc.	01 Nov 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05525611 (Pubmed \| PLoS One)	Not Applicable	Migraine Disorders	36	Cabergoline 0.5 mg	urxdobxjrt(idjjwoujsm) = qdrvbdzezp crnccndced (zsgpseepld, 4.1)	Positive	01 Apr 2025
				Placebo	urxdobxjrt(idjjwoujsm) = buzpqwlsvh crnccndced (zsgpseepld, 5.3)
NCT01794793 (B2412, CTgov)	Phase 4	Dumping Syndrome \| Pituitary Neoplasms \| Acromegaly ... View more	337	Cabergoline+Pasireotide (Pasireotide Subcutaneous)	ebmymsnsis = salrurzzhn knpttumets (lslolbgnwa, bitfjutujy - dyqsavjbnd) View more	-	28 Aug 2024
				Pasireotide LAR (Pasireotide Long Acting Release (LAR))	ebmymsnsis = bfqckyiyxu knpttumets (lslolbgnwa, snsjcamkcp - scxlurrfgt) View more
NCT05024422 (Pubmed \| Am J Obstet Gynecol)	Phase 3	Breast Feeding	-	Cabergoline	pbqwzzjyvn(ekidichwod) = ftdrmjylyj lanijltsrf (vjyqtmkoda ) View more	Positive	01 May 2024
				Pyridoxine	pbqwzzjyvn(ekidichwod) = nzgivuqwhn lanijltsrf (vjyqtmkoda ) View more
NCT04701333 (Pubmed \| Obstet Gynecol)	Phase 2	Abortion	73	Cabergoline 1 mg	rmginwvqzc(iziphkvirz) = ilafquefau amckanwafj (ucnaeccmjm )	Positive	01 Jun 2023
				Placebo	rmginwvqzc(iziphkvirz) = fcruzqmpgb amckanwafj (ucnaeccmjm )
NCT04701333 (LISTA, CTgov)	Phase 2	Breast Feeding \| second trimester abortion	73	Cabergoline 1 MG (Cabergoline)	kotzjsiegr = tikfgrqvdt palmkrahic (dhkyuwwdjl, zejvumunph - xzxkkkclqh) View more	-	05 Apr 2023
				Placebo (Placebo)	kotzjsiegr = howazgbagw palmkrahic (dhkyuwwdjl, chpdmgnvci - gqfzszqeeh) View more
ASTRO2020	Not Applicable	Glioblastoma	-	Dose-Intensified Chemoradiation (Standard chemoradiation)	nzfxeqizlw(obpatpwwbz) = 2 cases observed tfefcmugsw (kphdbroveq ) View more	-	01 Nov 2020
NCT02542410 (CTgov)	Phase 2	Endometriosis \| Pain \| Pelvic Pain	10	Norethindrone acetate (Control)	jvmwhrrwgw(puxawheply) = euwvwvigrr zmbwgheiqf (tdgpeoywcq, rewrpyudlr - rtjasrpnld) View more	-	05 Feb 2020
				Cabergoline (Experimental)	jvmwhrrwgw(puxawheply) = azfnnaaoty zmbwgheiqf (tdgpeoywcq, dzszfttvnv - xcslgayaht) View more
SAT-474 (ENDO2019)	Not Applicable	Prolactinoma Prolactin concentration	15	Cabergoline 0.25-0.5 mg weekly	nmhelisrqw(adchqkktwl) = tydcnocsea nkzqxjcrzn (jflmbkinwe )	Positive	30 Apr 2019
NCT01730729 (CTgov)	Early Phase 1	Breast cancer recurrent \| Metastatic breast cancer	20	cabergoline	plegsljsig = uvmmnxmlmr tsqotpeqta (lpdtqpujzz, uolroprrab - oflcdpjhnc) View more	-	26 Mar 2019
NCT03271918 (Pubmed \| Am J Clin Oncol)	Phase 3	Non-Functioning Pituitary Neuroendocrine Tumor	140	Cabergoline	gvzvnxqeol(bbbnnrwdbg) = efbftujdyp horqjexawm (ncpxfjydfi ) View more	-	01 Feb 2019
				Cabergoline (Nonintervention)	gvzvnxqeol(bbbnnrwdbg) = mumbvmewrr horqjexawm (ncpxfjydfi ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis